We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Restoring Mobility to Injured Spinal Cord

By Biotechdaily staff writers
Posted on 23 Aug 2006
Researchers successfully employed a combination of two strategies to regenerate nerves in the spinal cords of rats and restore movement. More...


The spinal cord is like a super highway of nerves. When an injury occurs, the body's policing defenses put up a roadblock in the form of a scar to prevent further injury, but this roadblock stops all neural traffic from moving forward.

The researchers, from Case Western Reserve University (Cleveland, OH, USA), bypassed this roadblock in the spinal cord. They first regenerated the severed nerve fibers, or axons, around the initial large lesion with a segment of peripheral nerve taken from the leg of the same animal that suffered the injury. Next, they jump-started neural traffic by allowing many nerve fibers to exit from the end of the bridge. This was done by using an enzyme that stopped growth inhibitory molecules from forming in the small scar that forms at the exit ramp of the bridge. This allowed the growing axons to reconnect with the spinal cord.

For more than 100 years, researchers have used grafts of peripheral nerves from the rib area or parts of the leg. Although peripheral nerves can be used successfully as grafts in the limbs, spinal cord injuries put up defenses called inhibitory chondroitin sulfate proteoglycans that create molecular guardrails within scars at the lesion site. These scars act as a barrier to regenerating axons and result in loss of the ability to breathe or move arms or legs, depending upon the injury site.

In the current study, about 20% of the nerve fibers left the bridge and reconnected with the spinal cord, which brought about a markedly improved mobility for the seven rats given the chondroitinase treatment, noted Jerry Silver, a professor of neurosciences at the Case School of Medicine and senior author of the study. In a control group of five rats that underwent the same procedure but were given a saline solution instead of chrondroitinase, none showed any nerve growth out of the bridge or improvement in their limbs.



Related Links:
Case Western Reserve University

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Gold Member
Pre- Eclampsia Control
Acusera Pre-Eclampsia Control
Japanese Encephalitis Test
Japanese Encephalitis Virus Real Time PCR Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Blood Test Measuring Tumor Proliferation May Guide Treatment Sequencing in Metastatic Melanoma

Metastatic melanoma remains difficult to manage because outcomes vary widely and early prognostic markers are limited. About half of patients carry a BRAF gene mutation, giving clinicians several first-line... Read more

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

Comprehensive Genomic Testing Expands Treatment Options for Advanced Cancers

Selecting effective therapies for advanced cancers remains difficult because standard tumor testing often targets only a limited set of genes. As options dwindle, many patients face decisions without strong... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.